IsoFlux1.png

IsoFlux - Liquid Biopsy System - Online Webinars

Attend live webinars about different research techniques being implemented with the IsoFlux Liquid Biopsy system.
All online Webinars are recorded for later viewing. Below is the latest presented.

Check this page regularly for upcoming online webinars, when one is scheduled, information and registration will appear below.

Upcoming Webinar


RECORDED ONLINE WEBINARS

 

 

ULTRA SENSITIVE SEQUENCING FOR LIQUID BIOPSY SAMPLES

Presented  on  October  27 2016

Please join Fluxion and Swift Biosciences for a detailed introduction of the new, ultra-sensitive Spotlight™ 59 Oncology Panel. 

Designed specifically for detection of mutations from liquid biopsy samples, Fluxion’s new Spotlight™ 59 Oncology Panel is a turnkey solution for use with Illumina sequencers. The high sensitivity of Spotlight™ 59 makes it ideal for CTCs, cfDNA, and other challenging sample types such as FFPE. Combined with ERASE-Seq, Fluxion’s statistically powered variant caller, Spotlight 59 delivers 100% specificity at 0.1% allele frequency detection.
 
The webinar covers: 
- Challenges in sensitive NGS detection with liquid biopsy samples
- Sources of sequencing error
- Spotlight 59 panel chemistry
- Spotlight 59 Workflow
- Novel ERASE-Seq methodology
- Data analysis workflow
- Spotlight 59 panel performance on analytical and clinical samples

Fluxion-Logo-PMS_s.png
 

 

 

SOMATIC MUTATION DETECTION FROM LIQUID BIOPSIES: THE ISOFLUX NGS WORKFLOW

Presented on November 3 2015

Speaker: Dr. Cristian Ionescu-Zanetti, CTO & Co-Founder Fluxion Biosciences

Introduction: Next generation sequencing (NGS) of blood-derived nucleic acids is an emerging paradigm for determining the mutational status of cancer patients over time. Here we present data from a CTC enrichment modality that results in tumor cell purities of >10% and a high sensitivity NGS data analysis workflow that enables the use of standard amplicon panels typically used for primary tissue. 
 
Methods:  Blood samples were enriched for CTCs using the IsoFluxTM System, from a starting blood volume of 7.5-14ml.  Matched samples were enumerated to determine the CTC load, where CTCs were defined as CK+, CD45- nucleated cells (DAPI+).  Cells were lysed and DNA was amplified using the IsoFlux NGS Kit (Fluxion Biosciences).  Targeted libraries were sequenced using both the MiSeq (Illumina) and PGM (ThermoFisher) sequencing instruments; data was analyzed using a customized variant calling/filtering pipeline.
 
Results: Multisite analytical validation data, based on spiking of cells into whole blood, demonstrated a detection limit down to 2 cells/ml blood. Clinical data from two different clinical pilot studies demonstrates the detection of somatic variants for a majority of samples, and significant overlap between detected mutations and known somatic mutation sites. This assay makes possible the detection of somatic variants from urological cancer patients without the need for a tissue biopsy.

 

ISOFLUX WEBINAR - ISOFLUX NGS WORKFLOW FOR CTC

Presented December 2 2014

The IsoFlux System is the first instrument of its kind to capture rare circulating tumor cells (CTCs) with sufficient recovery and purity to meet the demands of Next Generation Sequencing (NGS) applications. 
In this webinar, you'll see examples of how a complete workflow can be established in your own lab to track mutations in cancer samples, all using your own existing NGS pipeline. 

Topics will include: 
The promise of the blood biopsies in cancer management  | Sample challenges for NGS applications | NGS workflow overview | Use of the AmpliSeq Cancer Hotspot Panel v2 | Optimization of the variant calling and filtering in Ion Reporter | Analytical validation of CTC NGS assay | Clinical patient data using NGS assay

Speakers: 
Cristian Ionescu-Zanetti, CTO & Co-Founder Fluxion Biosciences
Christopher Davies, Director of Bioinformatics, IonTorrent / Thermo Fisher


VIEW MORE WEBINARS AT THE ISOFLUX Liquid BIOPSY WEBINAR LIBRARY